I have held CRX for too long, but initially bought on seeing the theoretical advantages of the "systems" for evaluation of drugs at potentially less costs than other systems.

I bought the shares initially long out and bought a number of times at lower and lower prices.

From the fundamentals it appears to be beginning to show profits, and projections are also good.

The charts point to a break out reversal which is being sustained.
On a 12-18ths time scale should do well. I wouldn't trade it, as the spread for me is too wide.

BDYOH

Results will be promising.

Cyprotex maintains its momentum
Business Financial Newswire
Drug discovery technology and information firm Cyprotex continues to perform well and remains ahead of the same period last year.

The firm said it has been an uncertain period for some customers and competitors alike and it has experienced reduced orders from a small number of important customers as a result.

But it said this has been offset by increased demand from other customers and for new products, reflecting the ongoing investment in new technology and equipment.

Chairman Steve Harris said: "Taking into account the historic seasonality of the business, which sees around 55% of revenues and a much larger proportion of profits generated in the second half, we remain confident in the outlook for the full year."

Cyprotex expects to announce its interim results for the six months to 30 June on the 12 August.

Sentiment seems to be pretty good with Crx right now.

Just done a dummy sale and the mm's are bidding above the mid price
for stock (5.4p) and it's breaking higher each day at the moment.

Daily Mail page 107..........very nice ....

Trading Update

Half Yearly Report
RNS
RNS Number : 1071L
Cyprotex PLC
07 August 2013



Press Release 7 August 2013



Cyprotex PLC
("Cyprotex" or "the Company")

Interim Results 2013

Strong first half performance delivers record profits



Cyprotex PLC (AIM: CRX), a specialist ADME-Tox Contract Research Organisation (CRO), today reports its interim results for the half year to 30 June 2013.





Financial Highlights



· Revenues up 22.3% to £4.55m (H1 2012: £3.72m)

- Revenues in Europe including UK up 33.7%

- Revenues in North America up 15%

- Reliance on any one individual large customer remains low at 12.6% of revenues

· Robust EBITDA of £703,000 (H1 2012: £89,000)

· Operating Profit of £317,000 (H1 2012: loss £189,000)

· Cash generated from operations at £588,000 (H1 2012: Cash used in operations £103,000)





Operational Highlights



· Very strong sales growth in UK, Europe and North America

· 78 new customer contracts signed (H1 2012: 88)

- 35 and 43 new customers for Macclesfield and Watertown operations respectively

- Three new strategic customers (i.e. where expected 12 month revenues are in excess of £250,000)

· 18 month collaborative research project in the area of predictive toxicology with Pfizer, announced in October 2012, is proceeding well

· US Environmental Protection Agency (EPA) contract of up to $10m over 5 years to support Phase 2 of the ToxCast programme

· Partnering deals with Sigma® Life Science, InSphero AG and Sirius Analytical Instruments Limited continue to make excellent progress

· New service offerings have rapidly attracted high value customers:

- Upgraded CellCiphr® high content screen for determination of hepatotoxicity has gained significant traction with customers

- eCiphrCardio, our new cardiotoxicology assay, was launched in February

· Significant investment in workhorse instrumentation. Continued investment is essential to keep Cyprotex at the forefront of automated liquid handling and analytical technologies:

- Upgraded mass spectrometry facility. A further two Waters Xevo® TQ mass spectrometers added in the period following the four in 2012 at a combined total cost of £994,000

- A second new robotic screening platform (TECAN Freedom EVO 200)

· Highly successful symposium held in Tokyo, Japan which has been followed by a targeted marketing and sales campaign





Post-Period Update



· Launch of a new Neurotoxicity assay, eCiphrNeuro, to evaluate neuronal activity of new drug candidates

· Significant institutional investor interest in the Company with Oryx International (27.3%), Henderson Global (6.95%), as new major investors

· Christopher Mills joined the Board of Cyprotex as Non-Executive Director.He is a director and investment manager of Oryx International Growth Fund

· £7 million in cash is being raised by way of an Open Offer and Placing of Loan Notes in the Company, fully underwritten by Harwood Capital LLP, to facilitate further investment in the US and assist with acquisitions



Steve Harris, Chairman of Cyprotex PLC, said:



"2013 has seen the most promising trading start to the financial year in the Company's history. The success has come from all geographical territories and from all parts of our technical service offering. It is particularly pleasing to note that our investments in improving our high content toxicity assay CellCiphr® and in our new cardiotoxicity assay e-CiphrCardio have been rewarded with excellent uptake. Additionally, we have secured two notable new deals in the last 12 months with a 5 year contract with the EPA worth up to $10m for supporting the ToxCast programme and the 18 month Research Collaboration agreement with Pfizer proceeding well. The Board remains confident of achieving market expectations for revenues and operating profits for the full year, prior to any potential impact from the EPA contract.

We also welcome our new investors and thank them for their commitment, through which we hope to maximise future opportunities and accelerate the growth of the Company."

Listen:Cyprotex - Interim Results 2013

Interview

Covered by Shares mag this week - Pre -clinical contract research organisation Cyprotex is going places. Chairman Steve Harris 7 Aug - '2013 has seen the most promising trading start to the financial year in the company's history'.
CEO Anthony Baxter 7 Aug - 'We expect sales growth to accelerate in the second half of the year as our widening portfolio of ADME and toxicity assays and newly signed customer strategic deals take effect'.


The spread of 7.4% spoils this one.

Trading Update

Executive Option Scheme

I always sell out the day before results or trading updates.

Stuff like this seems to happens alot.

Grant of Options

Further to the announcement made on 23 January, the Company announces today that Tony Baxter, Chief Executive Officer of the Company, has been granted -- options, all over ordinary shares of 0.1p each as part of the executive share option scheme.

The vesting of these executive options is on grant, at an exercise price of 6 pence per share, and are exercisable only upon change of control of the Company within a ten year period, dependent upon the Company's share price performance and subject to a minimum share price of 12 pence.

-Ends-

Final Results

Financial Highlights

· Strong revenue growth up 17.3% to £9.77 million (2012: £8.33 million)
· Operating profits up 88% at £0.61 million (2012: £0.33 million)
· Underlying EBITDA^, an indicator of cash generation, up 59% at £1.54 million (2012: £0.97 million)
· £6.88 million (net) raised by Company in total in September 2013
- £4 million by way of an issue of unsecured convertible loan notes; and
- £3 million of unsecured redeemable loan notes
· Loss after tax of £0.8 million (2012 Profit after tax: £0.2 million) due to exceptional non-cash finance charge relating to the issue of loan notes in the year of £1.6 million (2012: £nil)
· Loss per share at 0.36 pence (2012: earnings per share 0.09 pence)

^ excluding share-based payment charge and impairment of intangibles

Operational Highlights

· Strong performance across all divisions of the business
- 136 new customers generating £1.76 million of revenues
- Further de-risking of the business through a broadening customer base with our largest customer contributing less than 10% of revenues for the first time and top 5 customers accounting for 30.5%
· Increased investment in people and equipment
- Investment of £1.6 million in state of art liquid handling and analytical equipment
- Expansion of UK facility into Biohub at Alderley Park
- Increase in headcount to over 100 employees
· Alliances, collaborations and new contracts performing well
- US Environmental Protection Agency contract worth up to $10m over five years for ToxCast project
- Distribution agreement with Intralink to expand Cyprotex brand in the important Japanese market
- Evolution of Pfizer collaboration which now involves support work for specific projects
- Federated approach provides customers with a broad range of products and services
· Launch of eCiphrCardio and eCiphrNeuro, new proprietary services for the prediction of cardiotoxicity and neurotoxicity respectively
· Changes to the Board structure
- Ian Johnson joins as Chairman as Steve Harris becomes a Non-Executive Director
- Christopher Mills joins as Non-Executive Director following Chris Clothier departure

Post Period Events
· Acquisition of CeeTox Inc., a US specialist in in vitro toxicology screening for the personal care, cosmetics and industrial chemicals sectors

Expansion of Bioanalytical Capabilities

Cyprotex PLC (AIM:CRX), a specialist ADME-Tox Contract Research Organisation (CRO), today announces the expansion of their bioanalytical capabilities within the BioHub site at Alderley Park in the UK to increase its offering to both existing customers and new customers in new markets.

The new instruments include a Waters Xevo® G2-S QTof high resolution accurate mass spectrometer ("QTof"), a LabLogic Beta-Ram® radiochemical detector and a Waters Atmospheric Pressure Gas Chromatography (APGC) system. This investment enables Cyprotex to improve its services to its existing pharmaceutical customers as well as unlock future potential in new markets such as the chemical and personal care markets.

Assessing the metabolites formed following drug exposure is a key part of the drug development process. The Waters Xevo® G2-S QTof mass spectrometer is one of the most advanced instruments for this purpose. By determining the accurate mass of the metabolites it enables more precise structural characterisation to be achieved. The new QTof can also be linked to a LabLogic Beta-Ram® radiochemical detector which complements this service allowing detection of radiochemicals and quantification of radiolabelled metabolites formed.

Although our current analytical equipment is suitable for the majority of molecules we test, it is not appropriate for certain classes of compounds and chemicals. As Cyprotex expands into the personal care and chemicals market, an ability to analyse more volatile compounds is required. The Company has therefore invested in gas chromatography which is a more appropriate platform for these types of molecules. Another key trend in the market is the preclinical development of large molecules. The QTof can analyse an extended range of molecular weights meaning the analysis of larger molecules is more achievable.

Dr Anthony Baxter, Cyprotex's Chief Executive Officer, comments on the expansion of the bioanalytical facility:

"Characterising the structural identity of drug metabolites is a critical part of the drug development process. By investing in the QTof and the radiochemical detector we can now provide a comprehensive service which is appropriate for late stage preclinical development projects required by the regulatory authorities.

"As we expand into new markets we are observing a shift in the requirements for bioanalysis, and we are adapting our business accordingly. We now have a wide range of solutions to cover our differing customers' needs, allowing us to grow our existing business as well as attract customers from new markets."

Proposed Share Consolidation and Notice of General Meeting

Cyprotex PLC (AIM: CRX), a specialist ADME-Tox Contract Research Organisation (CRO), announces that it has today posted a circular to shareholders dated 3 July 2014 ("Circular") setting out details of a proposed consolidation of share capital (" Share Consolidation").

Under the Share Consolidation it is proposed that every 10 existing ordinary shares will be consolidated into one new ordinary share, with any fractional entitlements arising from the Share Consolidation being aggregated and sold in the market on behalf of the relevant Shareholders and the proceeds donated to charity.

The Board believes that the consolidation of share capital will result in a more appropriate number of shares in issue for a company of Cyprotex's size in the UK market. The Share Consolidation may also help to make the Shares more attractive to investors and may result in a narrowing of the bid/offer spread, thereby improving liquidity.

The Share Consolidation is subject to the approval of shareholders at a general Meeting which is being held at 11.00 a.m. on 24 July 2014. If the resolution is approved, trading in the consolidated shares should begin on 28 July 2014.

Following the Share Consolidation, Shareholders will still hold the same proportion of the Company's ordinary share capital as before the Share Consolidation (save in respect of fractional entitlements). Other than a change in nominal value, the New Ordinary Shares will carry equivalent rights under the Articles of Association to the Existing Ordinary Shares.

Further details of the Share Consolidation are set out in the Circular which will be made available on the Company's website at www.cyprotex.com.

The Definitions which apply in the Circular have been used in this announcement.

Has this consolidation gone thro' at 10-1?


Lost in France!

oui - 28 July 2014.

DC.

Mercy!


I thought so, but wished differently.


Hoping I could die a rich man.


Interesting company, which will probably be bought out at sometime or other.

Good luck Fred. :-))

A bit of life here since the New year?

I am still holding on to these and surprised to be in profit.

But still wonder if it will be bought out.

I thought it was a long distance runner when I bought.

But it seems a b, long track.

I've have a few and I'm nearly back to break even - I must try and remember why I bought them!

I know the feeling!

It was one of the last aim or small caps I bought!

One learns.

But why was I so bloody slow!

-----=--

Final Results

Cyprotex PLC (AIM: CRX), the preclinical ADME-Tox services company, today reports its final results for the year ended 31 December 2014.

Financial Highlights

· Strong revenue growth up 18.4% to £11.57 million (2013: £9.77 million)

· CeeTox acquisition contributed £1.12 million of total revenue

· Excluding CeeTox revenue grew 7.0% (2013: 17.3%)

· Gross margins decreased to 75.0% (2013: 80.0%) predominantly as a result of greater outsourcing in the period

· Operating loss of £0.71 million, excluding goodwill impairment, (2013: Operating profit of £0.61 million)

· Goodwill impairment relating to US Operations of £3.04 million (2013: £nil)

· Underlying EBITDA^ of £0.61 million (2013: £1.54 million)

· Loss per share at 18.59 pence (2013: loss per share 3.56 pence^^)

· Cash of £2.9 million as at 31 December 2014 (2013: £7.1 million)



^ excluding share-based payment charge and impairment of intangibles
^^ rebased following a ten for one share consolidation


Operational Highlights

· Acquisition and integration of CeeTox business completed

· Expanded into the BioHub at the former Astra Zeneca Alderley Park site, and transferred a number of assays and staff to accommodate further growth in revenues

· Significant investment in several major new products and services. These include a new High Throughput Facility in Watertown, a new suite of drug transporter assays, a new high resolution QTof mass spectrometer for improved metabolite identification services and new toxicology analysis equipment in Macclesfield

· Dependence on one large customer and one large Government agency has been reduced at Kalamazoo

· 171 new customers in 2014 (2013: 136 customers)

· 407 total customers served in 2014 (2013: 325 customers)

· Largest customer contributed 8.1% of revenues (2013: 9.8%)

· Commenced and completed two large contracts for the US Environmental Protection Agency (EPA)

more....

Trading Update

Trading update

The financial performance of the Company for the first 5 months of the year is ahead of expectations driven by strong growth in UK revenues and whilst there remain challenges, particularly in the US operations, the Board expects that its full year revenues and profits will exceed current market expectations.

Interim Results 2015 Revenues up significantly and return to operational profitability

Cyprotex PLC (AIM: CRX), a specialist ADME-Tox Contract Research Organisation (CRO), today reports its interim results for the half year to 30 June 2015.


Financial Highlights

· Revenues up 28% to £6.93 million (H1 2014: £5.41 million).
· Gross margins were 76.7% (H1 2014: 78.7%, FY 2014: 75.0%).
· Operating profit of £0.36 million (H1 2014: Operating loss £0.58 million).
· Underlying EBITDA^ of £1.10 million (H1 2014: £0.04 million).
· Cash of £4.13 million (H1 2014: £4.56 million, FY 2014: £2.93 million).

^ excluding share based payment charge

Operational Highlights

· The investment plan for all 4 sites which commenced in early 2014 and completed in early 2015 is now bearing fruit and has contributed significantly to the revenue growth seen in H1.
· Investment in a new drug transporter facility for the support of full drug-drug interaction studies for regulatory submission, QTof based metabolite identification and 3D tissue-based toxicology assays at our UK sites has been highly successful in revenue generation. Successful translocation of our existing toxicology facility to a second UK site at the BioHub, Alderley Park.
· Validation of a replica High Throughput (HT) ADME screening platform at our Watertown site has also been completed and the platform is now supporting large scale screening contracts for the US Government.
· Investment in upgrading our toxicology assays at our Kalamazoo site (formerly CeeTox) to bring them fully into OECD compliance has been completed and these assays, along with our proprietary SenCeeTox® skin sensitization assays have been well received by existing and new customers.
· Website upgrades including a new blog page have contributed to a noticeable improvement in the global recognition of the Cyprotex brand.
· 103 new customers in H1 2015 (111 in H1 2014).
· Successful completion and continued expansion of two large US Environmental Protection Agency (EPA) contracts.
· Largest customer is 12.3% (FY 2014: 7.8%) of revenues and represents a continuing large strategic deal with a major pharmaceutical company.

Post Period-End Highlights

· Expansion of Research & Development into regulatory genotoxicity services and the creation of a new Biosciences Division across all four global sites.

Trading Update

Trading update

The financial performance of the Company for the first nine months of the year is ahead of expectations driven by continuing strong growth in UK revenues and whilst there still remain challenges as referred to in previous announcements, particularly in the US operations which still need some attention but which are much improved from earlier in the year, the Board expects that its full year revenues and EBITDA will exceed current market expectations.

That will be a quid!

That will be £1.16!

130p touched earlier.

Final Results

Financial Highlights

· Strong revenue growth up 34.9% to £15.61 million (2014: £11.57 million)

· Gross margins increased to 77.3% (2014: 75.0%)

· Operating profit of £1.98 million, (2014: Operating loss, excluding goodwill impairment, of £0.71 million)

· Underlying EBITDA^ of £3.40 million (2014: £0.61 million)

· Cash generated from operations of £3.48 million (2014: used in operations £1.32 million)

· Exceptional non-cash finance charge in respect of Embedded Derivative associated with Loan Notes of £8.07 million (2014: finance income £0.24 million) yielding a basic loss per share at 28.99 pence (2014: loss per share 18.59 pence)

· Underlying basic earnings^^ per share of 6.94 pence (2014: loss 19.67 pence)

· Cash of £5.4 million as at 31 December 2015 (2014: £2.9 million)

^ excluding share-based payment charge and impairment of intangibles
^^ excluding movement in Embedded Derivative valuation associated with Redeemable and Convertible Loan Notes

Operational Highlights

· New Bioscience division for phenotypic and target based drug discovery service

· Partnership in the EC-funded EU-ToxRisk Consortium with an estimated value of €1 million over 6 year period

· Expansion of 3D cellular model capabilities with introduction of beating cardiac microtissue

· Launched new software solutions, chemPKTM and chemTox as virtual screening approaches for predicting pharmacokinetics and toxicity

· New blog launched on Cyprotex website and increased social media presence

· 243 new customers in 2015 (2014: 171 customers)

· 488 total customers served in 2015 (2014: 407 customers)

· Largest customer contributed 9.6% of revenues in 2015 (2014: 8.1%)

Trading Update

Cyprotex PLC, the preclinical ADME-Tox services company, provides an update on revenue and profit guidance for the first quarter of 2016.

The financial performance of the Company for the first quarter of the year is significantly ahead of the Boards' expectations, comparative period performance and internal budgets.

The Board also confirms that the Company's strategic review is progressing.

Trading Update and Notice of Interim Results


Cyprotex PLC, the preclinical ADME-Tox services company, provides an update on revenue and profit guidance for the first half of 2016.

The financial performance of the Company for the first half of the year is significantly ahead of the Boards expectations, comparative period performance and internal budgets.

The Board expects to announce the Interim Results of the Company on 2 August 2016.

The Board also confirms that the Company's strategic review is progressing.

This announcement contains inside information.

Interim Results

Revenue growth and increase in profitability continue into 2016

Cyprotex PLC (AIM: CRX), a specialist ADME-Tox Contract Research Organisation (CRO), today reports its interim results for the half year to 30 June 2016.


Financial Highlights

· Revenues up 26% to £8.73 million (H1 2015: £6.93 million).
· Gross margins were 77.5% (H1 2015: 76.8%).
· Operating profit up significantly to £1.49 million (H1 2015: £0.36 million).
· Underlying EBITDA^ increased to £2.34 million (H1 2015: £1.10 million).
· Cash of £6.82 million (H1 2015: £4.13 million, FY 2015: £5.41 million).

^ excluding share based payment charge of £0.13 million (H1 2015: £0.08 million)

Operational Highlights

· Significant increase in new customers to 139 (H1 2015: 103).
· Watertown revenues in H1 2016, up almost 70% from the comparative period, benefitting from the general improvement in the investment environment in the East Coast of USA.
· Demand for high value drug-drug interaction packages and metabolite identification has been strong and has assisted in growing revenues ahead of expectations.
· Our presence at Alderley Park BioHub site has increased with the opening of a new bioanalytical laboratory to allow for planned expansion of these services later in the year and the expansion our toxicology facility. Proprietary 3D cellular models have been highly successful in revenue generation.
· Validation of a High Throughput (HT) ADME screening platform at our Watertown site has been completed and is supporting large scale screening contracts for the US Government and other customers.
· Upgrading of our toxicology assays at Kalamazoo to provide in vitro GLP genotoxicity services has already seen positive customer interest.
· Website upgrades and social media engagement have increased the global recognition of the Cyprotex brand.
· Revenue from the largest customer accounts for 10.3% (FY 2015: 9.6%) of total revenue and represents continuing business with a major pharmaceutical company.

Ian Johnson, Chairman of Cyprotex PLC, said:

"I am delighted to report that the progress made in 2015 has continued into 2016 and, as previously flagged to the market, we are substantially ahead of our expectations. The growth of the business is global and from an increasingly wide range of industries and sectors. Investment in all sites, which commenced in 2014, continues and is delivering high quality new services which contributed to the increase in revenue in H1 2016. Watertown and both UK sites have grown revenues and consequently operational profitability. The Kalamazoo site has received considerable investment to launch a suite of GLP genotoxicity services which we expect will drive revenue growth for the site in the second half of the year. Of note is the collaboration with Cytocentrics announced in February 2016 where we are developing a full range of ion channel services to meet the expected regulatory changes in cardiac safety testing as a consequence of the CiPA initiative. The second half has started well and the Board looks forward to the remainder of the year with continued confidence."

This announcement contains inside information for the purposes of Article 7 of EU regulation 596/2014.

Announcement: Recommended Offer

Posting of Scheme Document